| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Carole Ben-Maimon is President and CEO at LRMR. Carole Ben-Maimon's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $935K at current prices.
Net of sales, the LRMR filings show accumulation of 36,746 shares.
Carole Ben-Maimon has 11 Form 4 filings on record from June 2020 to January 2026, all as President and CEO at Larimar Therapeutics (LRMR), 2020–2026.
The 15 reported transactions were 8 option or other derivative awards, 4 stock awards, 2 open-market purchases and 1 other transaction.
Counted by filing, the open-market trades come to 2 purchases worth about $119K and no sales.
The largest open-market purchase was 31,746 shares of LRMR at an average $3.15 on September 16, 2022, about $100K. Twelve months later LRMR was up 33%.